Market Closed -
Nasdaq
04:30:01 2024-05-03 pm EDT
|
5-day change
|
1st Jan Change
|
1.77
USD
|
-0.56%
|
|
+14.94%
|
-20.63%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
88.51
|
147.5
|
174
|
50.94
|
82.97
|
66.87
|
-
|
-
|
Enterprise Value (EV)
1 |
88.51
|
147.5
|
174
|
50.94
|
82.97
|
66.87
|
66.87
|
66.87
|
P/E ratio
|
-0.95
x
|
-1.49
x
|
-4.88
x
|
-1.06
x
|
1.6
x
|
-7.31
x
|
80.5
x
|
1.52
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
731
x
|
-
|
13.2
x
|
10
x
|
0.59
x
|
2.15
x
|
1.65
x
|
0.59
x
|
EV / Revenue
|
731
x
|
-
|
13.2
x
|
10
x
|
0.59
x
|
2.15
x
|
1.65
x
|
0.59
x
|
EV / EBITDA
|
-
|
-2,889,865
x
|
-
|
-598,289
x
|
-
|
-
|
-
|
-
|
EV / FCF
|
-1,651,269
x
|
-
|
-
|
-603,706
x
|
-
|
-
|
-2,396,783
x
|
5,265,373
x
|
FCF Yield
|
-0%
|
-
|
-
|
-0%
|
-
|
-
|
-0%
|
0%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
9,726
|
19,280
|
28,520
|
32,657
|
37,208
|
37,780
|
-
|
-
|
Reference price
2 |
9.100
|
7.650
|
6.100
|
1.560
|
2.230
|
1.770
|
1.770
|
1.770
|
Announcement Date
|
3/11/20
|
3/29/21
|
3/29/22
|
3/31/23
|
3/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
0.121
|
-
|
13.16
|
5.091
|
140.1
|
31.17
|
40.65
|
113.6
|
EBITDA
|
-
|
-51.04
|
-
|
-85.15
|
-
|
-
|
-
|
-
|
EBIT
1 |
-48.92
|
-51.15
|
-60.84
|
-85.76
|
72.67
|
-11.1
|
-1.142
|
72.11
|
Operating Margin
|
-40,430.58%
|
-
|
-462.19%
|
-1,684.48%
|
51.85%
|
-35.62%
|
-2.81%
|
63.48%
|
Earnings before Tax (EBT)
1 |
-53.71
|
-58.33
|
-35.95
|
-67.51
|
67.18
|
-9.737
|
-0.2726
|
73.64
|
Net income
1 |
-53.71
|
-55.18
|
-32.87
|
-62.81
|
67.04
|
-9.737
|
-0.6526
|
72.78
|
Net margin
|
-44,388.43%
|
-
|
-249.68%
|
-1,233.73%
|
47.84%
|
-31.24%
|
-1.61%
|
64.08%
|
EPS
2 |
-9.600
|
-5.150
|
-1.250
|
-1.470
|
1.390
|
-0.2420
|
0.0220
|
1.166
|
Free Cash Flow
|
-53.6
|
-
|
-
|
-84.39
|
-
|
-
|
-27.9
|
12.7
|
FCF margin
|
-44,296.69%
|
-
|
-
|
-1,657.57%
|
-
|
-
|
-68.64%
|
11.18%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
17.45%
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/11/20
|
3/29/21
|
3/29/22
|
3/31/23
|
3/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
0.516
|
0.597
|
0.687
|
1.323
|
1.557
|
1.524
|
1.13
|
131.5
|
1.761
|
5.797
|
0.303
|
4.242
|
13.22
|
13.47
|
0.8625
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-19.44
|
-22.3
|
-19.74
|
-21.74
|
-21.8
|
-22.48
|
-10.68
|
116.5
|
-10.1
|
-23.06
|
-9.793
|
-5.972
|
2.516
|
2.148
|
-8.52
|
Operating Margin
|
-3,767.64%
|
-3,734.84%
|
-2,873.07%
|
-1,643.08%
|
-1,400.19%
|
-1,475.13%
|
-945.31%
|
88.63%
|
-573.42%
|
-397.88%
|
-3,231.95%
|
-140.78%
|
19.03%
|
15.95%
|
-987.83%
|
Earnings before Tax (EBT)
1 |
-0.655
|
-29.24
|
-10.15
|
-13.34
|
-29.58
|
-14.43
|
-33.88
|
122.3
|
-1.757
|
-19.45
|
-9.414
|
-5.653
|
2.841
|
2.509
|
-7.711
|
Net income
1 |
-0.605
|
-29.24
|
-5.451
|
-13.34
|
-29.58
|
-14.43
|
-33.88
|
122.3
|
-1.757
|
-19.59
|
-9.414
|
-5.653
|
2.841
|
2.509
|
-7.711
|
Net margin
|
-117.25%
|
-4,898.32%
|
-793.45%
|
-1,008.69%
|
-1,900.06%
|
-946.78%
|
-2,997.88%
|
93.01%
|
-99.77%
|
-337.86%
|
-3,107%
|
-133.26%
|
21.49%
|
18.63%
|
-894.03%
|
EPS
2 |
-0.0200
|
-1.050
|
-0.1700
|
-0.3100
|
-0.6200
|
-0.2900
|
-0.7100
|
2.460
|
-0.0400
|
-0.3900
|
-0.1940
|
-0.1180
|
0.0340
|
0.0280
|
-0.1600
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/10/21
|
3/29/22
|
5/12/22
|
8/15/22
|
11/9/22
|
3/31/23
|
5/10/23
|
8/14/23
|
11/13/23
|
3/28/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-53.6
|
-
|
-
|
-84.4
|
-
|
-
|
-27.9
|
12.7
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
0
|
-
|
-
|
-
|
2
|
2
|
2
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
6.42%
|
4.92%
|
1.76%
|
Announcement Date
|
3/11/20
|
3/29/21
|
3/29/22
|
3/31/23
|
3/28/24
|
-
|
-
|
-
|
Last Close Price
1.77
USD Average target price
6.875
USD Spread / Average Target +288.42% Consensus |
1st Jan change
|
Capi.
|
---|
| -20.63% | 66.87M | | +21.85% | 546B | | -4.77% | 359B | | +16.97% | 323B | | +5.69% | 290B | | +13.68% | 234B | | +3.65% | 198B | | -11.12% | 194B | | +8.08% | 167B | | -3.40% | 157B |
Other Pharmaceuticals
|